sub:assertion {
  <http://purl.obolibrary.org/obo/DOID_5844> biolink:category biolink:Disease .
  sub:association rdf:object <http://purl.obolibrary.org/obo/DOID_5844> ;
    rdf:predicate biolink:treats ;
    rdf:subject <https://identifiers.org/drugbank:DB00934> ;
    a rdf:Statement ;
    rdfs:label "Maprotiline hydrochloride tablets are contraindicated in patients hypersensitive to maprotiline and in patients with known or suspected seizure disorders. It should not be given concomitantly with monoamine oxidase (MAO) inhibitors. A minimum of 14 days should be allowed to elapse after discontinuation of MAO inhibitors before treatment with maprotiline is initiated. Effects should be monitored with gradual increase in dosage until optimum response is achieved. The drug is not recommended for use during the acute phase of myocardial infarction." ;
    biolink:provided_by <https://w3id.org/um/NeuroDKG> ;
    biolink:relation schema:MedicalContraindication .
  <https://identifiers.org/drugbank:DB00934> biolink:category biolink:Drug .
}